OpGen, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christian-Laurent Benoit Bonte
- Full Time Employees
- 85
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 9717 Key West Avenue Rockville MD United States of America 20850
- IPO Date
- May 5, 2015
- CIK
- 0001293818
- Website
- opgen.com
- Similar Companies
- Business
- OpGen, Inc. (Nasdaq: OPGN) develops and commercializes molecular diagnostics solutions and AI-driven bioinformatics to combat infectious diseases, antimicrobial resistance, and diseases of the microbiome. The company offers products including the Acuitas AMR Gene Panel for detecting antimicrobial resistance genes in bacterial pathogens; the ARESdb cloud-based database for surveillance of resistance trends; the QuickFISH BC real-time PCR assay for rapid identification of bloodstream pathogens; and the Curetis NGS-based metagenomics platform for comprehensive pathogen detection. Services encompass AI-powered genomic analysis, pathogen surveillance, and customized bioinformatics pipelines for clinical and research applications. Founded in 2007 and headquartered in Gaithersburg, Maryland, OpGen operates primarily in the United States and Europe, targeting hospitals, clinical laboratories, public health organizations, and research institutions in the molecular diagnostics and precision medicine segments. In recent developments, OpGen announced a strategic partnership with the University of Maryland School of Medicine in 2024 to advance AI-driven genomic surveillance for hospital-acquired infections; completed a $5 million funding round in early 2025 led by existing institutional investors to support Acuitas platform expansion; and launched the next-generation ARESdb 2.0 with enhanced machine learning capabilities for real-time AMR prediction in October 2025.
OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
OpGen Announced 1-for-10 Reverse Stock Split
OpGen Provides Update on Business Operations and Strategic Opportunities
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
OpGen Announces Acquisition of Preferred Stock by David Lazar
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
Why Is OpGen (OPGN) Stock Up 540% Today?
Why Is OpGen (OPGN) Stock Up 115% Today?
OpGen, Inc. (OPGN) Q2 2023 Earnings Call Transcript
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
OpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
Buy 5 Top-Ranked Stocks With Rising P/E in July
Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns